5-ALA-Induced Fluorescent Urine Cytology in Comparison with Conventional Cytology, BTA-TRAK, and NMP-22 Tests in the Diagnosis of Bladder Cancer

Rajendra B Nerli; Shadab Rangrez; Shridhar C. Ghagane; Parth Lalakia; Shoubhik Chandra; Shreya Chandra

doi:10.1055/s-0044-1791752

Brazilian Journal of Oncology (Jan 2025)

5-ALA-Induced Fluorescent Urine Cytology in Comparison with Conventional Cytology, BTA-TRAK, and NMP-22 Tests in the Diagnosis of Bladder Cancer

Rajendra B Nerli,
Shadab Rangrez,
Shridhar C. Ghagane,
Parth Lalakia,
Shoubhik Chandra,
Shreya Chandra

Affiliations

Rajendra B Nerli: ORCiD; Department of Urology and Urologic Oncology, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research (Deemed-to-be-University), Belagavi, Karnataka, India
Shadab Rangrez: Department of Urology and Urologic Oncology, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research (Deemed-to-be-University), Belagavi, Karnataka, India
Shridhar C. Ghagane: ORCiD; Dr. Prabhakar Kore Basic Science Research Centre, KLE Academy of Higher Education and Research (Deemed-to-be-University), Belagavi, Karnataka, India
Parth Lalakia: College of Population Health, Office of Global Affairs, Thomas Jefferson University, Philadelphia, United States
Shoubhik Chandra: Department of Urology and Urologic Oncology, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research (Deemed-to-be-University), Belagavi, Karnataka, India
Shreya Chandra: Department of Pathology, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research (Deemed-to-be-University), Belagavi, Karnataka, India

DOI: https://doi.org/10.1055/s-0044-1791752
Journal volume & issue: Vol. 21

Abstract

Read online

Introduction To assess the sensitivity fluorescent urine cytology induced by 5-aminolevulinic acid (5-ALA) in the diagnosis of bladder cancer and to compare the sensitivity and specificity with currently available markers approved by the United States Food and Drug Administration (FDA), bladder tumour antigen (BTA-TRAK, Bard Diagnostic Sciences, Redmond, WA, United States) assay based on enzyme-linked immunosorbent assay (ELISA), nuclear matrix protein 22 (NMP-22), and conventional cytology.

Published in Brazilian Journal of Oncology

ISSN: 2526-8732 (Online)
Publisher: Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia
Country of publisher: Brazil
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.brazilianjournalofoncology.com.br/

About the journal

Abstract

Keywords